Sarcopenia Treatment Market Expected to Reach $4,704 Million by 2030

According to a new report published by Allied Market Research, titled, “Sarcopenia treatment market by treatment, route of administration, and distribution channel: global opportunity analysis and industry forecast, 2021–2030," The global sarcopenia treatment market size was valued at $2,577 million in 2020, and is projected to reach $4,704 million by 2030, registering a CAGR of 6.1% from 2021 to 2030.

Sarcopenia is a condition characterized by loss of skeletal muscle mass and function. Although it is primarily a disease of the elderly, its development may be associated with conditions that are not exclusively seen in older people. Low muscle mass or gradual loss, overall weakness, and lower stamina are the common symptoms of sarcopenia, which affects physical activity levels. Lower physical activity levels also further contribute to muscle shrinkage.

Major factors that are expected to boost the growth of the sarcopenia treatment market during the forecast period are the rise in incidence of the elderly population and the growing acceptance of vitamins and dietary supplements. Furthermore, increase in cases of sarcopenia is further anticipated to propel the growth of the sarcopenia treatment market. Also, increase in R&D activities for the treatment of sarcopenia is further estimated to boost the growth of the sarcopenia treatment market. In addition, rise in cases of malnutrition because of poor nutritional intake will further provide potential opportunities for the growth of the sarcopenia treatment market in the coming years.

However, rise in price of protein supplement and the inaccessibility of sarcopenia treatment drugs is expected to further challenge the growth of the sarcopenia treatment market in the near future. Furthermore, rise in R&D activities for introduction of novel drugs and advancements in diagnostics technologies to develop superior drug delivery system are anticipated to propel the market for sarcopenia treatment.

Coronavirus (COVID-19) was discovered in late December in Hubei province of Wuhan city in China. The disease is caused by a virus, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans. Lockdown, government regulations, and continuous increase in infection rate across the country created a widespread financial impact on neurology hospitals and clinics. Large number of hospitals and clinics have witnessed a drop in number of patient visits amid COVID-19 ultimately reducing client contact.

The impact of COVID-19 pandemic is expected to remain positive for the sarcopenia treatment market. As sarcopenia patients are more vulnerable to COVID-19 infection which cause systematic inflammation that results into loss of skeletal muscle. Furthermore, in older persons, the need for social isolation during the COVID-19 pandemic has led to protein deficiency and decrease in daily physical activity which accelerates the loss of muscle strength and function. Persons with diagnosed COVID-19 are also likely to have 2 or 3 weeks of decreased physical functions resulting in secondary sarcopenia which led to increase in demand of protein supplements which promotes the muscle growth. Thus, such factors are having impacted the market growth positively in COVID-19.

The sarcopenia treatment market is segmented into treatment, route of administration, distribution channel, and region.

On the basis of treatment, the market is categorized into vitamin B12 supplement, Vitamin D & Calcium supplement, protein supplements and others. Presently, the protein supplements segment dominated the global market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed owing to increase in the prevalence of malnutrition deficiency across the globe, increase in R & D activities for the novel therapies, drugs and supplements are expected to boost growth of the sarcopenia treatment market.

By distribution channel, the market is categorized into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. The homecare segment is anticipated to depict significant growth during the forecast period. This is attributed to rise in the incidence of the elderly population and the growing acceptance of vitamins and dietary supplements. Moreover, owing to rapid increase of sarcopenia rate in geriatric population, technological advancements, and lifestyle change drives the growth of the market.

Key Findings Of The Study

• By treatment, the protein supplement segment witnessed the highest growth with a CAGR of 5.9% in the global sarcopenia treatment market in 2020.
• By route of administration, the oral segment held the largest market share in 2020 and is expected to remain dominant throughout the forecast period.
• By distribution channel, the hospital pharmacies segment exhibits the fastest growth and is expected to grow at a CAGR of 5.5% from 2021 to 2030.
• By region, Asia-Pacific is expected to experience a growth at the highest rate, registering a CAGR of 7.5% during the forecast period.

In 2020, Asia-Pacific dominated the market for sarcopenia treatment and held the largest revenue share in 2020, highest growth rate majorly due to changing lifestyle conditions, increasing geriatric population, and increasing healthcare facilities. Furthermore, increase in R&D activities for development of novel therapies and rise in prevalence of the sarcopenia disease will further boost the growth of the sarcopenia treatment market in the region during the forecast period.